N-[2-(1H-Indol-3-yl)ethyl]sulfuric diamide | 205487-30-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-[2-(1H-Indol-3-yl)ethyl]sulfuric diamide
• 英文别名: 3-[2-(sulfamoylamino)ethyl]-1H-indole
• CAS: 205487-30-5
• 化学式: C₁₀H₁₃N₃O₂S
• mdl: MFCD26144728
• 分子量: 239.3
• InChiKey: RLTYIVHOXGKVPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  96.4
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS<br/>[FR] TRYPTAMINE SULFONAMIDES EN TANT QU'ANTAGONISTES DE 5-HT6
  申请人：MERCK & CO INC

  公开号：WO2009073118A1

  公开（公告）日：2009-06-11

  Novel compounds of the structural formula (I) are antagonists of the 5-HT6 receptor and are useful in the treatment, prevention and suppression of diseases mediated by the 5-HT6 receptor. The compounds of the present invention are useful in the treatment of obesity, diabetes, metabolic disorder, cognitive disorders, age related cognitive disorder, depression, mania, bipolar disorders, schizophrenia, anxiety, generalized anxiety disorder, panic disorder, and obsessive compulsive disorder, epilepsy, convulsions, migraine, substance withdrawal from substances including but not limited to opiates, nicotine, tobacco products, alcohol, benzodiazepines, sedatives, and the like, sleep disorders, attention deficit/hyperactivity disorder, and Alzheimer's disease.

  结构式（I）的新化合物是5-HT6受体的拮抗剂，并且可用于治疗、预防和抑制由5-HT6受体介导的疾病。本发明的化合物可用于治疗肥胖症、糖尿病、代谢紊乱、认知障碍、老年认知障碍、抑郁症、躁狂症、双相情感障碍、精神分裂症、焦虑症、广泛性焦虑障碍、恐慌症、强迫症、癫痫、惊厥、偏头痛、戒断物质包括但不限于鸦片制剂、尼古丁、烟草制品、酒精、苯二氮平类药物、镇静剂等的戒断症状、睡眠障碍、注意力缺陷/多动障碍和阿尔茨海默病的治疗。
• TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS
  申请人：Pasternak Alexander

  公开号：US20100256106A1

  公开（公告）日：2010-10-07

  Novel compounds of the structural formula (I) are antagonists of the 5-HT 6 receptor and are useful in the treatment, prevention and suppression of diseases mediated by the 5-HT 6 receptor. The compounds of the present invention are useful in the treatment of obesity, diabetes, metabolic disorder, cognitive disorders, age related cognitive disorder, depression, mania, bipolar disorders, schizophrenia, anxiety, generalized anxiety disorder, panic disorder, and obsessive compulsive disorder, epilepsy, convulsions, migraine, substance withdrawal from substances including but not limited to opiates, nicotine, tobacco products, alcohol, benzodiazepines, sedatives, and the like, sleep disorders, attention deficit/hyperactivity disorder, and Alzheimer's disease.

  结构式（I）的新型化合物是5-HT6受体拮抗剂，并可用于治疗、预防和抑制由5-HT6受体介导的疾病。本发明的化合物可用于治疗肥胖症、糖尿病、代谢紊乱、认知障碍、老年认知障碍、抑郁症、躁狂症、双相情感障碍、精神分裂症、焦虑症、广泛性焦虑障碍、恐慌症、强迫症、癫痫、惊厥、偏头痛、从阿片类、尼古丁、烟草制品、酒精、苯二氮卓类、镇静剂等物质的物质戒断、睡眠障碍、注意力缺陷/多动障碍和阿尔茨海默病。
• US8138219B2
  申请人：——

  公开号：US8138219B2

  公开（公告）日：2012-03-20